ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,050.61
-0.39%
Dow Jones
43,449.90
-0.61%
US Dollar vs MXN
20.14593
-0.16%
Brent Oil
73.395
0.40%
Bitcoin
105,111.36
-0.98%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Regulus Therapeutics Inc (RGLS)

  7. Regulus Therapeutics Inc (RGLS) Noticias

RGLS

Regulus Therapeutics (RGLS)

Regulus Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RGLS
FechaHoraFuenteTítuloSímboloCompañía
26/11/202407:00PR Newswire (US)Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
08/11/202413:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RGLSRegulus Therapeutics Inc
07/11/202415:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGLSRegulus Therapeutics Inc
07/11/202415:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
07/11/202415:05PR Newswire (US)Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
08/10/202407:00PR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
28/08/202407:00PR Newswire (US)Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
08/08/202415:05PR Newswire (US)Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
06/08/202407:00PR Newswire (US)Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
29/07/202415:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
24/06/202409:00AllPennyStocks.comThis Biotech Wasted No Time Stealing The Premarket ShowNASDAQ:RGLSRegulus Therapeutics Inc
24/06/202406:00PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
04/06/202407:00PR Newswire (US)Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® IndexesNASDAQ:RGLSRegulus Therapeutics Inc
20/05/202415:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGLSRegulus Therapeutics Inc
16/05/202407:00PR Newswire (US)Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerNASDAQ:RGLSRegulus Therapeutics Inc
09/05/202415:54Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RGLSRegulus Therapeutics Inc
09/05/202415:05PR Newswire (US)Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
06/05/202407:00PR Newswire (US)Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
30/04/202407:00PR Newswire (US)Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast SeriesNASDAQ:RGLSRegulus Therapeutics Inc
21/03/202415:05PR Newswire (US)Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
12/03/202405:32PR Newswire (US)Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of EquityNASDAQ:RGLSRegulus Therapeutics Inc
12/03/202405:30PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
09/01/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RGLSRegulus Therapeutics Inc
02/01/202415:05PR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
27/12/202315:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RGLSRegulus Therapeutics Inc
22/11/202307:00PR Newswire (US)Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
09/11/202315:05PR Newswire (US)Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
02/11/202307:00PR Newswire (US)Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
19/10/202307:00PR Newswire (US)Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
20/09/202306:00PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RGLS

Su Consulta Reciente

BIT
UB0JNS
UniCredit Bank
EU
0043N
Natixis Sa null
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados